Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101 Given Orally (Twice Daily Dosing for 5 Consecutive Days in a 21-day Period) in Patients With Advanced Malignancies Expressing the Biomarker HR23B

Next Previous
Trial Profile

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101 Given Orally (Twice Daily Dosing for 5 Consecutive Days in a 21-day Period) in Patients With Advanced Malignancies Expressing the Biomarker HR23B

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zabinostat (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Follicular lymphoma; Head and neck cancer; Hodgkin's disease; Lung cancer; Lymphoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peripheral T-cell lymphoma; Solid tumours; T-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; First in man

Most Recent Events

  • 17 Oct 2022 Status changed from active, no longer recruiting to completed.
  • 07 Apr 2022 2-year survival of cancer patient treated with zabadinostat monotherapy results published in the Celleron Therapeutics Media Release
  • 06 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top